Gangjee A, Devraj R, McGuire J J, Kisliuk R L
Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, Pennsylvania 15282, USA.
J Med Chem. 1995 Sep 15;38(19):3798-805. doi: 10.1021/jm00019a009.
Variation of the bridge linking the heterocyclic ring and p-aminobenzoyl-L-glutamate portions of our previously described classical 2,4-diaminofuro[2,3-d]pyrimidines 1 and 2 are reported as inhibitors of dihydrofolate reductase (DHFR) and thymidylate synthase (TS) and as antitumor agents. Specifically -CH2CH2- and -CH2NHCH2- bridged analogues, N-[4-[2-(2,4-diaminofuro[2,3-d]pyrimidin-5-yl) ethyl]benzoyl]-L-glutamic acid (3) and N-[4-[[N-[(2,4-diaminofuro[2,3-d]pyrimidin-5-yl) methyl]amino]methyl]benzoyl]-L-glutamic acid (4), respectively, were synthesized. Compound 3 was obtained via a Wittig reaction of the tributylphosphonium salt of 2,4-diamino-5-(chloromethyl)furo[2,3-d]pyrimidine (5) and methyl 4-formylbenzoate (6) followed by reduction and coupling with the diethyl ester of L-glutamic acid. Compound 4 was synthesized by the nucleophilic displacement of 5 with diethyl N-[4-(aminomethyl)benzoyl]-L-glutamate (15) and saponification. Both analogues were evaluated in vitro as inhibitors of DHFRs from (recombinant) human, human CCRF-CEM cells, and Lactobacillus casei. Compound 3 showed moderate activity (IC50 10(-6)-10(-7) M). Compound 4 was essentially inactive (IC50 10(-5) M, CCRF-CEM). The compounds were also evaluated against TS from (recombinant) human and L. casei and were of low activity (IC50 10(-5) M). The three-atom-bridged analogue 4 was somewhat more inhibitory to human TS than methotrexate (MTX). Compound 3 inhibited the growth of tumor cells in culture (IC50 10(-7) M) while 4 showed a low level of growth inhibitory activity. The inhibition of the growth of leukemia CCRF-CEM cells by both compounds parallels their inhibition of CCRF-CEM DHFR. Analogue 3 was a good substrate for human folylpolyglutamate synthetase (FPGS) derived from CCRF-CEM cells (Km 8.5 microM). Further evaluation of the growth inhibitory activity of 3 against the MTX-resistant subline of CCRF-CEM cells (R30dm) with decreased FPGS indicated that poly-gamma-glutamylation was important for its action. Protection studies with 3 in the FaDu squamous cell carcinoma cell line indicated that inhibition was completely reversed by leucovorin [(6R,S-5-formyltetrahydrofolate] or by a combination of thymidine and hypoxanthine, suggesting an antifolate effect directed at DHFR.
据报道,我们之前描述的经典2,4 - 二氨基呋咱并[2,3 - d]嘧啶1和2中连接杂环和对氨基苯甲酰 - L - 谷氨酸部分的桥连结构的变体,可作为二氢叶酸还原酶(DHFR)和胸苷酸合成酶(TS)的抑制剂以及抗肿瘤剂。具体而言,分别合成了 - CH₂CH₂ - 和 - CH₂NHCH₂ - 桥连的类似物,即N - [4 - [2 - (2,4 - 二氨基呋咱并[2,3 - d]嘧啶 - 5 - 基)乙基]苯甲酰] - L - 谷氨酸(3)和N - [4 - [[N - [(2,4 - 二氨基呋咱并[2,3 - d]嘧啶 - 5 - 基)甲基]氨基]甲基]苯甲酰] - L - 谷氨酸(4)。化合物3是通过2,4 - 二氨基 - 5 - (氯甲基)呋咱并[2,3 - d]嘧啶(5)的三丁基鏻盐与4 - 甲酰基苯甲酸甲酯(6)的Wittig反应,随后还原并与L - 谷氨酸二乙酯偶联得到的。化合物4是通过用N - [4 - (氨基甲基)苯甲酰] - L - 谷氨酸二乙酯(15)对5进行亲核取代并皂化合成的。两种类似物均在体外作为来自(重组)人、人CCRF - CEM细胞和干酪乳杆菌的DHFR抑制剂进行了评估。化合物3表现出中等活性(IC50为10⁻⁶ - 10⁻⁷ M)。化合物4基本无活性(IC50为10⁻⁵ M,CCRF - CEM)。这些化合物还针对来自(重组)人和干酪乳杆菌的TS进行了评估,活性较低(IC50为10⁻⁵ M)。三原子桥连的类似物4对人TS的抑制作用比甲氨蝶呤(MTX)稍强。化合物3在培养中抑制肿瘤细胞生长(IC50为10⁻⁷ M),而4显示出低水平的生长抑制活性。两种化合物对白血病CCRF - CEM细胞生长的抑制作用与其对CCRF - CEM DHFR的抑制作用平行。类似物3是来自CCRF - CEM细胞的人叶酸聚谷氨酸合成酶(FPGS)的良好底物(Km为8.5 μM)。对3对FPGS降低的CCRF - CEM细胞的MTX抗性亚系(R30dm)的生长抑制活性的进一步评估表明,多聚γ - 谷氨酰化对其作用很重要。在FaDu鳞状细胞癌细胞系中用3进行的保护研究表明,亚叶酸钙[(6R,S - 5 - 甲酰基四氢叶酸)]或胸苷和次黄嘌呤的组合可完全逆转抑制作用,表明针对DHFR的抗叶酸作用。